Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Tanabe Pharma Corporation has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners across 2 distinct art units. This structure shows that the company's current active cases are being treated as separate technical matters by the patent office, with no shared personnel or departmental oversight.
MOU, LIYUAN is the busiest examiner for this portfolio, currently overseeing 1 pending office action. With a total of 2 pending office actions, this examiner is responsible for a portion of the company's active prosecution. The involvement of 2 distinct art units indicates that the biotechnology or pharmaceutical subject matter of the applications is distinct enough to require review by different specialized units.
Practitioners must develop separate strategies for each of the 2 distinct examiners. Because the cases are in 2 distinct art units, the procedural and technical expectations may differ between them. The 1 pending office action handled by MOU, LIYUAN represents a share of the portfolio's current activity, while the other matter is managed by a different examiner in a separate unit, requiring individualized attention.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOU, LIYUAN | 1 | 43.8% | +59.9% |
| CERIONI, DANIEL LEE | 1 | 64.3% | +28.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18247015 | NEUROMUSCULAR DISEASE EVALUATION SYSTEM | CERIONI, DANIEL LEE | 84d |
| 19323465 | PHARMACEUTICAL COMPOSITION FOR HAILEY-HAILEY DISEASE AND USE THEREOF | MOU, LIYUAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18247015 | NEUROMUSCULAR DISEASE EVALUATION SYSTEM | CERIONI, DANIEL LEE | 84d |
| 19323465 | PHARMACEUTICAL COMPOSITION FOR HAILEY-HAILEY DISEASE AND USE THEREOF | MOU, LIYUAN | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 3791 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19323465 | PHARMACEUTICAL COMPOSITION FOR HAILEY-HAILEY DISEASE AND USE THEREOF | MOU, LIYUAN | 1628 | §103§112 | Final Rejection | — | Pending | Sep 09, 2025 |
| 18247015 | NEUROMUSCULAR DISEASE EVALUATION SYSTEM | CERIONI, DANIEL LEE | 3791 | §101§103§112 | Final Rejection | 84d | Pending | Mar 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTanabe Pharma Corporation has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Liyuan Mou has the most, with 1 of Tanabe Pharma Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
